問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
林泰祺
下載
2025-08-25 - 2026-12-25
Condition/Disease
Test Drug
Participate Sites1Sites
Recruiting1Sites
2025-09-01 - 2030-06-30
Participate Sites7Sites
Recruiting7Sites
2021-08-15 - 2026-05-31
Participate Sites8Sites
Recruiting8Sites
2023-11-16 - 2027-01-31
Participate Sites5Sites
Recruiting5Sites
2025-01-01 - 2030-02-01
2025-02-03 - 2029-01-31
2021-11-01 - 2031-12-31
2019-08-01 - 2022-03-31
neovascular age-related macular degeneration (TALON)
Brolucizumab (RTH258)
Participate Sites4Sites
Recruiting4Sites
2021-01-07 - 2023-06-08
Not yet recruiting1Sites
Recruiting3Sites
全部
